STOCK TITAN

Hims & Hers Health Form 144 reveals $3.21M insider share sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Hims & Hers Health, Inc. (HIMS) – Form 144 filing: An unnamed insider has notified the SEC of a proposed sale of 60,000 Class A shares, representing roughly 0.03 % of the 217.6 million shares outstanding. The shares have an aggregate market value of $3,214,880.58 and are expected to be sold on or about 08/06/2025 through the NYSE using Fidelity Brokerage Services.

The shares derive from two equity-compensation events:

  • 39,721 shares acquired on 02/28/2022 via a stock-option exercise paid in cash.
  • 20,279 shares vested on 06/15/2025 as restricted-stock compensation.
No other sales have been reported in the past three months. The filer affirms no undisclosed adverse information and acknowledges Rule 10b5-1 representation requirements.

This filing signals an intended discretionary liquidation by a company affiliate; while small relative to total float, it may be interpreted by investors as a modest insider-sentiment data point.

Positive

  • Sale represents only ~0.03 % of shares outstanding, limiting potential market impact.
  • Proper Rule 144 disclosure suggests adherence to insider-trading compliance and transparency.

Negative

  • Insider selling $3.2 M in stock may be perceived as a bearish sentiment signal.

Insights

TL;DR: Insider plans to sell 60k HIMS shares (~$3.2M); minor fraction of float, mildly negative sentiment.

Rule 144 filings reveal insider intent before trades occur. Here, the volume equals ~0.03 % of outstanding shares—too small to create material price pressure, yet still notable because insider selling can signal personal liquidity or valuation views. The stock-option exercise (Feb 2022) and RSU vesting (Jun 2025) show standard compensation cycles, suggesting the sale may be routine diversification rather than a bearish call. Impact: limited.

TL;DR: Filing is procedural; sale size immaterial to control, neutral governance impact.

The Form 144 satisfies disclosure rules for affiliates selling >5,000 shares or >$50k in value. No red flags emerge: timely notice, reputable broker, and required representations included. Lack of past-90-day sales supports compliance with aggregation limits. Governance risk remains low; however, continued insider liquidation could draw scrutiny if pattern persists.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many HIMS shares are being sold under this Form 144?

60,000 Class A shares are slated for sale.

What is the total market value of the proposed HIMS share sale?

The aggregate market value is $3,214,880.58.

When is the planned sale date for the HIMS shares?

Approximately 08/06/2025.

On which exchange will the HIMS shares be sold?

The shares are intended to be sold on the NYSE.

How were the shares to be sold originally acquired?

39,721 shares via stock-option exercise (02/28/2022) and 20,279 shares via RSU vesting (06/15/2025).

Has the insider sold any HIMS shares in the last three months?

No. The filing notes "Nothing to Report" for prior 3-month sales.